Jagsonpal Pharmaceuticals Ltd - 507789 - Closure of Trading Window
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and BSE circular LlST/COMP/01/2019-20 dated April 2, 2019; this is to inform you that Trading Window, for dealing in shares of the Company, shall be closed with effect from July 1, 2019 till 48 hours from the declaration of Unaudited Quarterly Financial Results for the quarter ended on 30.06.2019 Jagsonpal Pharmaceuticals Ltd - 507789 - Pursuant To Regulation 23 (9) Of The SEBI (Listing Obligations And Disclosure Requirements) (Amendment) Regulations, 2018, Disclosure Of Related Party Transaction For The Financial Year Ended March 31, 2019.
Pursuant to Regulation 23 (9) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, please find enclosed disclosure of Related Party Transaction, in the format specified in the Accounting Standard for the financial year ended March 31, 2019. This is for your information and records. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Update Of Declaration With Regard To Unmodified Opinion On Audited Financial Results For The Quarter And Year Ended March 31, 2019.
With reference to your email dated June 17, 2019, we are giving the declaration with regard to unmodified opinion on Audited Financial Results for the quarter and year ended 31 March, 2019. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Audited Results For The Year Ended 31/03/2019
Sir/Madam, Please find attached herewith audited financial results for the year ended 31/03/2019 and the results were approved and taken by record by the Board of directors at their meeting held on 28/05/2019. You are requested to take the same on record. Thanking you, R K KAPOOR Compliance Officer Cum Company secretary. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board recommends Dividend
Jagsonpal Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on May 28, 2019, inter alia, has recommended Dividend @ 5% on Equity shares of Rs. 5/- each paid-up i.e. Rs. 0.25/- per share. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Outcome of Board Meeting
Sir, This is to inform you that the of Directors of the Company at their meeting held today (i.e. Tuesday the 28th day of May 2019commenced at 12.00 noon and concluded on 3.35 pm at the registered office, have inter alia , approved and taken on record the as per attachment. Thnx R K Kapoor Compliance Officer cum Co. Secretary JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report15/05/2019 3 Name of the Certifying Firm MUKESH ARORA & CO. 4 Name of the Certifying Individual MUKESH ARORA 5Membership TypeFCS 6 Membership Number 4819 7 CP No. 4405 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Intimation for Approval Of Financial Results, Declaration Of Dividend, If Any And Approval Of Notice Along With Director''s Report.
JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2019 ,inter alia, to consider and approve 1. To consider and approve the Standalone Audited Financial Results of the Company for the quarter and year ended 31st March, 2019 along with half yearly Statement of Assets & Liabilities; 2. To consider and take on record the Statutory Auditor's Report on Standalone Audited Financial Results of the Company for the year ended 31st March, 2019; 3. To consider Dividend, if any; 4. To approve the notice of 40th Annual General Meeting; 5. To approve Draft Director's Report together with other relevant reports; 6. To consider and approve the E- Voting facility from NSDL; 7. To fix the Book Closure date and cut-off date for the purpose of Annual General Meeting; 8. To appoint Scrutinizer for conducting E-voting; 9. Any other matters; Kindly note the same and acknowledge the receipt. Jagsonpal Pharmaceuticals Ltd - 507789 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayJAGSONPAL PHARMACEUTICALS LTD. 2CININE048B01027 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 60080000 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: R K KAPOOR Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: cakapoorrk@gmail.com Name of the Chief Financial Officer: SANJIV KUMAR DUDEJA Designation: CFO EmailId: nandita.singh@jagsonpal.com Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.